---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-010962"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T03:48:04.526754+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Coherus BioSciences stockholders elect directors, ratify auditor, approve say-on-pay at 2023 annual meeting

## Summary
- Elected Class III directors Dennis M. Lanfear (57.4M for) and Mats L. Wahlström (42.6M for) to hold office until 2026.
- Ratified Ernst & Young as independent auditor for FY 2023 with 65.4M votes for, 0.4M against.
- Approved non-binding advisory say-on-pay resolution for named executive officers with 55.4M for, 3.2M against.
- Approximately 65.9M shares voted out of 80.5M shares outstanding as of April 10, 2023 record date.

## SEC filing metadata
- accession: 0001558370-23-010962
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837023010962/0001558370-23-010962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837023010962/chrs-20230607x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-010962
- JSON: https://secwatch.observer/filing/0001558370-23-010962.json
- Plain text: https://secwatch.observer/filing/0001558370-23-010962.txt

## Key facts
- Shareholder Votes
  Coherus Oncology, Inc. shareholders approved Election of Class III Directors: Dennis M. Lanfear and Mats L. Wahlström at the 2023-06-07 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: Proposal 1. The Company’s stockholders elected by a majority of votes cast both of the Class III director nominees below, Dennis M. Lanfear and Mats L. Wahlström, to the Board to hold office until the 2026 annual meeting of stockholders or until their successors are elected. ​ ​ ​ ​ ​ ​ BROKER ​ NOMINEE ​ FOR WITHHELD NON- ​ VOTES ​ Dennis M. Lanfear 57,378,374 ​ 1,424,977 ​ 7,102,965 ​ ​ Mats L. Wahlström 42,646,152 ​ 16,157,199 ​ 7,102,965
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837023010962/0001558370-23-010962-index.htm
- Shareholder Votes
  Coherus Oncology, Inc. shareholders approved Non-binding advisory resolution to approve the compensation of the Company's named executive officers (Say-on-Pay) at the 2023-06-07 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: Proposal 3. The Company’s stockholders approved a non-binding, advisory resolution to approve the compensation of the Company’s named executive officers (a “Say-on-Pay” vote). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BROKER FOR AGAINST ABSTAIN NON-VOTES 55,379,513 ​ 3,233,870 ​ 189,968 ​ 7,102,965
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837023010962/0001558370-23-010962-index.htm
- Shareholder Votes
  Coherus Oncology, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ BROKER FOR AGAINST ABSTAIN NON-VOTES 65,375,866 ​ 434,987 ​ 95,463 ​ 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837023010962/0001558370-23-010962-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.